Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Copaxone Preview - StreetInsider.com

Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $17.00. Analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone, biosimilars potential, modest m-enox revenue stream. The stay on the ...

Canaccord Genuity Maintains a 'Buy' on Teva Pharma (TEVA); Adjusting Estimates; Copaxone Still In Focus - StreetInsider.com

Canaccord Genuity maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00. Analyst, Randall Stanicky, said, "New CEO Jeremy Levin provided a guidance update and business review today that brought a lot of attention but ultimately a flat ...

Momenta: The perfect Massachusetts success story - Boston Globe

Now Momenta is awaiting approval to sell a second generic: a version of the multiple sclerosis treatment Copaxone, made by Israel’s Teva Pharmaceutical Industries Ltd. Like generic Lovenox, the MS drug promises to reduce costs for patients and ...

Momenta Pharmaceuticals' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) - Seekingalpha.com

We have an ANDA under review for a generic Copaxone and we also have initiated a proof of concept clinical study for a novel product M402 a novel oncology product, which we are initiating a trial for in pancreatic cancer. We use intellectual property to ...

Teva Issues 2012 Outlook - Analyst Blog - NASDAQ

Meanwhile, branded products are expected to contribute $8.0 billion to the top line with multiple sclerosis drug, Copaxone, contributing $3.8 billion. Copaxone sales are expected to peak in 2012 and decline through 2015 with the entry of new competitors.

Teva's New CEO: A Positive Catalyst Going Forward - Seekingalpha.com

Some of that was reversion to mean, but fatigue with missed estimates and continued concern over the company's dependence on its multiple sclerosis drug Copaxone also contributed. In terms of revenue and earnings growth, Yanai's time should be viewed as successful.

UPDATE: Morgan Stanley Lowers Teva Pharmaceutical's PT - Benzinga

Relative valuation is discounted on ‘13E P/E, but inline on ‘15E. We await strategic updates and Copaxone news flow." Morgan Stanley maintains its Equal-weight rating on Teva Pharmaceuticals, which closed Friday at $38.61.

Teva cuts 2012 profit and sales forecasts - Businessweek

Teva still expects $3.8 billion in sales of its biggest brand-name product, the multiple sclerosis treatment Copaxone, and it maintained its forecast of $1 billion in sales of over-the-counter medications. However it expects lower sales of its ...

Prolor May Seek Partner to Market Growth Hormone Product - Bloomberg

Teva, which paid $6.5 billion to acquire U.S. biotechnology company Cephalon Inc. last year, needs new sources of revenue as its top-selling treatment, a branded multiple-sclerosis medicine called Copaxone, faces increased competition.

Has Momenta Pharmaceuticals Become the Perfect Stock? - Motley Fool

If Momenta can't get approval of its Copaxone generic, it could see itself move much further away from perfection. No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a ...